Vernalis to raise £22 million to fund pipeline
This article was originally published in Scrip
Vernalis plans to raise just over £22 million in net proceeds through a fully underwritten placing and open offer of almost 800 million new ordinary shares at three pence each. This represents a 26% discount to the previous day's closing price of 4.05 pence.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.